外周T细胞淋巴瘤(PTCL)是一组高度异质性的淋巴细胞异常恶性增殖性疾病,其发病率具有明显的地域差异。在中国,PTCL发病例数约占非霍奇金淋巴瘤(NHL)的25%~30%,显著高于欧美国家的10%~15%。传统化疗方案对于PTCL的疗效并不理想,组蛋白去乙酰化酶(HDAC)抑制剂作为一种新型抗肿瘤药物,已在复发或难治性PTCL治疗中取得了显著成果。近年来已有3个HDAC抑制剂上市用于此适应证,包括美国FDA批 Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous lymphoproliferative malignant proliferative diseases with obvious regional differences. In China, the incidence of PTCL accounts for about 25% -30% of non-Hodgkin’s lymphoma (NHL), which is significantly higher than 10% -15% in Europe and the United States. Traditional chemotherapy regimens are not ideal for the treatment of PTCL. Histone deacetylase (HDAC) inhibitors, as a new anti-tumor drug, have achieved remarkable results in the treatment of recurrent or refractory PTCL. In recent years, three HDAC inhibitors have been marketed for use in this indication, including the U.S. FDA approval